stable coronary artery disease
Conditions
Interventions
None listed
Sponsors
Department of Healthcare Economics and Health Policy, Graduate School of Medicine, The University of Tokyo
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: This study identified a stable CAD in the subjects for analysis from the database using information including age when treatment was received, main disease (International Classification of Diseases 10th Revision: ICD-10), and treatment history. Out of ICD-10 code I11.0 through I50.9, eligibility criteria included patients with a disease code indicating stable CAD, adults aged 20 years or older, and patients undergoing testing or diagnosis related to the degree of anatomical coronary stenosis or functional ischemia severity for the first time: computed tomography angiography (CTA), stress myocardial perfusion imaging (MPI), coronary angiography (CAG), or coronary fractional flow reserve (FFR). Subjects were followed up for at least 1 year (excluding cases of mortality).
Exclusion criteria
Exclusion criteria: The exclusion criteria were as follows: prior coronary revascularization, history of ACS within 1 year before the index day, and any latent risk factors that could affect the evaluation of cardiac disease diagnosis and treatment, such as cardiac-related surgery, assisted circulation or arrhythmia device implantation. We also excluded cases thought to have a low risk of cardiac disease. These included patients undergoing CTA alone for whom stress electrocardiogram (ECG) or stress echocardiography had not been performed within 1 year before the index day, patients undergoing CAG alone who had undergone the same testing two or more times (excluding follow-up CAG), and patients not treated with anti-platelet agents within 6 months after CAG (excluding cases considered to have no coronary stenosis). Patients who underwent coronary revascularization within 5 days after the index day were excluded because they were considered to have a very high risk of coronary disease and/or to be high priority emergency cases. Patients with concurrent systemic diseases, including malignant tumors or Kawasaki disease (sequela), as well as general injuries, were excluded because these factors could affect prognosis and medical costs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint is cost-effectiveness analysis (CEA). | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary endpoints are major adverse coronary events (MACEs) or life years (LYs unit: year) and medical costs. CEA was the ratio of the related medical costs for over 36 months and LYs (US$/LY). | — |
Countries
Japan
Contacts
Public ContactTomoyuki Takura
The University of Tokyo Department of Healthcare Economics and Health Policy, Graduate School of Medicine,
Outcome results
None listed